Transrectal Ultrasound Examination of the Prostate: Complications and Acceptance by Patients
Article first published online: 26 NOV 2008
© 1993 British Journal of Urology
British Journal of Urology
Volume 71, Issue 4, pages 457–459, April 1993
How to Cite
AUS, G., HERMANSSON, C. G., HUGOSSON, J. and PEDERSEN, K. V. (1993), Transrectal Ultrasound Examination of the Prostate: Complications and Acceptance by Patients. British Journal of Urology, 71: 457–459. doi: 10.1111/j.1464-410X.1993.tb15992.x
- Issue published online: 26 NOV 2008
- Article first published online: 26 NOV 2008
- Accepted for publication 6 February 1992
Summary— Transrectal ultrasound scan (TRUS) of the prostate was performed on 511 patients, 391 of whom also underwent between 1 and 5 transrectal 1.2 mm core biopsies. The infection rate in the whole group was 4.1%; 32% of the patients were given antibiotic prophylaxis with norfloxacin 400 mg twice daily for 1 week and in this group the infection rate was 0.8%. In the remaining patients, who received 400 mg norfloxacin at the time of biopsy and another 400 mg the same evening, the infection rate was 5.6%. The only risk factor identified for post–biopsy infection was steroid medication.
Only minor discomfort (or none at all) was reported by 95% of patients during the examination procedure. If TRUS was combined with core biopsy 92% reported either minor or no discomfort. Of 78 patients who experienced both finger-guided fine needle aspiration biopsy and TRUS-guided core biopsy 82% preferred the latter procedure.
TRUS and core biopsy proved acceptable to most patients. Antibiotic treatment with 2 tablets of norfloxacin failed to prevent infection.